The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective

被引:36
|
作者
El Khoury, Antoine C. [1 ]
Vietri, Jeffrey [2 ]
Prajapati, Girish [3 ]
机构
[1] Merck & Co Inc, West Point, PA 19486 USA
[2] Kantar Hlth, Princeton, NJ 08540 USA
[3] AllSource PPS, Huntington Beach, CA 92647 USA
关键词
Hepatitis C virus; Work impairment; Indirect costs; Direct costs; Health-related quality of life; QUALITY-OF-LIFE; GENOTYPE; HEALTH; HCV; PRODUCTIVITY; RIBAVIRIN; THERAPY; PEGINTERFERON; BOCEPREVIR; TELAPREVIR;
D O I
10.1007/s10620-012-2233-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) infection is widespread and associated with high economic costs and reduced quality of life, but the impact of untreated HCV infection on patient outcome is not well understood. To estimate the impact of untreated HCV infection on work productivity, daily activity, healthcare use, economic costs, and health-related quality of life (HRQoL). Respondents to the 2010 US National Health and Wellness Survey (n = 75,000) reporting physician diagnosis of HCV infection but not current or previous treatment (patients) were matched to respondents without HCV infection (controls) by use of propensity scores. Those reporting infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) were excluded. Self-reported work impairment, activity impairment, healthcare resource use, and HRQoL were compared between patients and controls. Indirect and direct costs were estimated. A total of 306 patients met inclusion criteria. Patients were more impaired at work than controls, with overall work impairment of 26 % versus 15 %, respectively (P < 0.001), mostly because of presenteeism in both groups. Annual productivity losses were estimated at $10,316 per employed patient compared with $5,469 per control (P < 0.001). Patients used more healthcare, with all-cause healthcare costs estimated at $22,818 per patient annually, compared with $15,362 per control (P < 0.001). HRQoL and activity impairment were also worse among patients than controls. Untreated HCV infection is associated with substantial economic costs to society, through loss of productivity and increased use of healthcare resources, and with impaired well-being of the patient.
引用
收藏
页码:2995 / 3003
页数:9
相关论文
共 50 条
  • [21] Grazoprevir + elbasvir for the treatment of hepatitis C virus infection
    Alric, Laurent
    Bonnet, Delphine
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (05) : 735 - 742
  • [22] Determination of the burden of hepatitis C virus infection in Ireland
    Thornton, L.
    Murphy, N.
    Jones, L.
    Connell, J.
    Dooley, S.
    Gavin, S.
    Hunter, K.
    Brennan, A.
    EPIDEMIOLOGY AND INFECTION, 2012, 140 (08) : 1461 - 1468
  • [23] New treatments for chronic hepatitis C virus infection
    Corouge, M.
    Pol, S.
    MEDECINE ET MALADIES INFECTIEUSES, 2011, 41 (11): : 579 - 587
  • [24] Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture
    Sepulveda-Crespo, Daniel
    Luis Jimenez, Jose
    Gomez, Rafael
    Javier De La Mata, Francisco
    Majano, Pedro L.
    Angeles Munoz-Fernandez, Ma
    Gastaminza, Pablo
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017, 13 (01) : 49 - 58
  • [25] Hepatitis C virus infection and the brain
    Weissenborn, Karin
    Tryc, Anita B.
    Heeren, Meike
    Worthmann, Hans
    Pflugrad, Henning
    Berding, Georg
    Bokemeyer, Martin
    Tillmann, Hans L.
    Goldbecker, Annemarie
    METABOLIC BRAIN DISEASE, 2009, 24 (01) : 197 - 210
  • [26] Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation
    Antonini, Teresa Maria
    Furlan, Valerie
    Teicher, Elina
    Haim-Boukobza, Stephanie
    Sebagh, Mylene
    Coilly, Audrey
    Bonhomme-Faivre, Laurence
    Roque-Afonso, Anne-Marie
    Vittecoq, Daniel
    Samuel, Didier
    Taburet, Anne-Marie
    Duclos-Vallee, Jean Charles
    AIDS, 2015, 29 (01) : 53 - 58
  • [27] Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: "A Flood of Opportunity''
    Gane, E. J.
    Agarwal, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (05) : 994 - 1002
  • [28] The Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection
    Kirdar, Sevin
    Yasa, Mehmet Hadi
    Aydin, Neriman
    Korkmazgil, Berna Gultekin
    Ozturk, Serife Barcin
    Omurlu, Imran Kurt
    MEANDROS MEDICAL AND DENTAL JOURNAL, 2015, 16 (03): : 108 - 113
  • [29] Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs
    Beste, Lauren A.
    Ioannou, George N.
    EPIDEMIOLOGIC REVIEWS, 2015, 37 (01) : 131 - 143
  • [30] Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease
    Strohbehn, Ian A.
    Seethapathy, Rituvanthikaa
    Lee, Meghan
    Sise, Meghan E.
    KIDNEY360, 2021, 2 (08): : 1316 - 1325